C-RAD

Legal Proceedings Report • Feb 22, 2024

The Supreme Court denies to leave appeal

The Supreme Court denies leave to appeal in the case regarding a former employee's claim for compensation for an invention.

The Supreme Court ruling means that the case is finally adjudicated and the ruling by the Patent and Market Court of Appeal therefore stands. Both C-RAD and the counterpart had sought leave to appeal to the Supreme Court.

As a consequence of the decision from the Supreme Court, C-RAD will recognize a provision of approximately SEK 10 million, covering past time and until today's date. For products using the invention described in the patent applications US12/632526 or PCT/SE2010 /051338, C-RAD is obliged to pay a 1 % royalty on net sales to the counterpart, up until 7th of December 2029.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com Christoffer Herou, CFO, +46 (0)725 82 86 16, investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

This information is information that C-RAD is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-22 12:38 CET.

Attachments

The Supreme Court denies to leave appeal